Protagonist Therapeutics (NasdaqGM:PTGX) 2026 Conference Transcript

Protagonist Therapeutics Conference Call Summary Company Overview - Company: Protagonist Therapeutics (NasdaqGM:PTGX) - Focus: Peptide therapeutics, with a history of development since 2008, aiming to address unmet medical needs through innovative oral peptide solutions [5][6] Key Points and Arguments Product Pipeline and Development - Late-Stage Assets: Protagonist has two late-stage partnered assets expected to receive approval in 2026, with outstanding Phase 3 data [5][6] - Partnerships: Collaborations with big pharma, such as Takeda and Johnson & Johnson, provide financial flexibility and support for R&D [6][27] - Rusfertide: Targeting polycythemia vera, with a priority review received, aiming for approval in Q3 2026. The disease affects approximately 100,000 patients in the U.S. [14][15][18] - Icotrokinra: Partnered with J&J, targeting psoriasis with promising Phase 3 data and an NDA filed in July 2025, expected approval in Q3 2026 [29][30] Market Opportunities - Rusfertide: Addresses uncontrolled hematocrit levels in polycythemia vera, a significant unmet need in treatment options [17][18] - Icotrokinra: Positioned as the first oral IL-23 antagonist, with a large market opportunity as 75%-90% of injectable patients may switch to an oral option [34][35] - Obesity Market: Protagonist is developing oral triple agonists, which could treat billions of patients, differentiating from existing injectable options [77][78] Financial Aspects - Royalty Structure: For rusfertide, a 21% royalty on the first $1.5 billion in sales, increasing to 29% thereafter. This structure supports the decision to opt-out of full partnership with Takeda [20][21][23] - Sales Milestones: Expected sales milestones for icotrokinra and rusfertide combined are projected at $1.2 billion, with achievable targets [31][32] Future Developments - PN-881: Currently in Phase 1 studies, targeting IL-17 blockers, with data expected in Q3 2026 to determine further development [60][63] - Anti-Obesity Candidates: Development of both oral and subcutaneous triple agonists, with clinical proof of concept expected soon [78][83] - Financial Stability: The company has a strong balance sheet, allowing for continued investment in its pipeline without the need for shareholder dilution [92] Additional Important Insights - Differentiation Strategy: Protagonist aims to create unique solutions in crowded markets by focusing on oral formulations and addressing specific unmet needs [8][12] - Safety and Efficacy: Emphasis on the safety profile of new drugs, particularly for chronic conditions where long-term treatment is necessary [49][50] - Market Dynamics: The company is aware of the competitive landscape and is strategically positioning its products to capture market share from existing therapies [41][42] This summary encapsulates the key insights from the Protagonist Therapeutics conference call, highlighting the company's strategic direction, product pipeline, market opportunities, and financial outlook.